| 產品詳情 |
| Edit |   |
|---|
| Product Name | MK-2206 |
|---|
| Description | A highly selective non-ATP competitive allosteric Akt inhibitor with IC50's of 8 nM, 2 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. MK-2206 potently inhibits phosphorylation of Thr308 and Ser473 in 3T3-L1 adipocytes with IC50 values of 0.11 and 0.18 μM, respectively as well as downstream effects of insulin on GLUT4 translocation (IC50 = 0.47 μM) and glucose transport (IC50 = 0.14 μM). In addition, treatment with MK-2206 causes a robust, concentration-dependent activation of autophagy in human glioma cell lines LN229 and T98G. MW: 480.39. Purity ≥98% by HPLC |
|---|
| Size | 1 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 8-(4-(1-Aminocyclobutyl)phenyl-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride |
|---|
| Gene, Accession, CAS # | CAS: 1032350-13-2 |
|---|
| Catalog # | 1888-1000 |
|---|
| Price | |
|---|
| Order / More Info | MK-2206 from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產品資料 |
|
|